# Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin

> **NCT00742859** · PHASE2 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 508 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** betrixaban
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT00742859
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-08
- **Final completion:** 2009-11
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00742859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00742859, "Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00742859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*